stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Total debt
HUTCHMED (China) Limited Sponsored ADR's total debt at the end of fiscal 2025 was $93.2M, up 12.5% from $82.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $94.5M. Over the past ten years it has ranged from $30.6M (fiscal 2018) to $410.8M (fiscal 2021); the current reading is higher than 91% of that period. HUTCHMED (China) Limited Sponsored ADR ranks 36th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $93.2M | 12.50% |
| FY2024 | $82.8M | 4.36% |
| FY2023 | $79.3M | 49.58% |
| FY2022 | $53.0M | (87.09%) |
| FY2021 | $410.8M | 572.27% |
| FY2020 | $61.1M | (4.01%) |
| FY2019 | $63.7M | 108.14% |
| FY2018 | $30.6M | (16.76%) |
| FY2017 | $36.7M | (21.47%) |
| FY2016 | $46.8M | (6.14%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $94.5M | 1.45% |
| Dec 2025 | $93.2M | (0.30%) |
| Jun 2025 | $93.4M | 12.85% |
| Dec 2024 | $82.8M | 0.86% |
| 19 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PRGO Perrigo Company plc compare | $3.3B |
| PBH Prestige Consumer Healthcare Inc. compare | $2.0B |
| ALVO Alvotech compare | $1.3B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $839.4M |
| TRLV Trulieve Cannabis Corp. compare | $345.0M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR | $94.5M |
| ANIP ANI Pharmaceuticals, Inc. compare | $23.4M |
| RGC Regencell Bioscience Holdings Limited compare | $463.7K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement